Genmab’s EPKINLY® Combination Therapy Gains FDA Approval for Follicular Lymphoma

Genmab ( (GMAB) ) just unveiled an update.

On November 18, 2025, Genmab A/S announced that the U.S. FDA approved EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma. This approval is significant as it marks the first FDA approval for a bispecific combination therapy in the lymphoma space, potentially setting a new standard of care. The approval was based on the Phase 3 EPCORE® FL-1 trial, which demonstrated superior progression-free survival and overall response rates compared to standard treatments. The approval could enhance Genmab’s positioning in the oncology market and provide new treatment options for patients with follicular lymphoma.

The most recent analyst rating on (GMAB) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab A/S is a biotechnology company based in Denmark, specializing in the development of antibody therapeutics for the treatment of cancer. The company focuses on innovative therapies, with a market emphasis on hematological cancers and solid tumors.

Average Trading Volume: 2,110,388

Technical Sentiment Signal: Buy

Current Market Cap: $18.66B

For an in-depth examination of GMAB stock, go to TipRanks’ Overview page.